Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

European Journal of Cancer

Volumn 50, Issue 18, 2014, Pages 3125-3135

  Moehler, M ^a   Maderer, A ^a   Schimanski, C ^b   Kanzler, S ^c   Denzer, U ^d   Kolligs, F T ^e   Ebert, M P ^f   Distelrath, A ^g   Geissler, M ^h   Trojan, J ⁱ   Schutz M ^a   Berie, L ^a   Sauvigny, C ^a   Lammert, F ^j   Lohse, A ^d   Dollinger, M M ^k   Lindig, U ^l   Duerr, E M ^e   Lubomierski, N ⁱ   Zimmermann, S ^j   Wachtlin, D ^m   Kaiser, A K ^m   Schadmand Fischer, S ^a   Galle, P R ^a   Woerns, M ^a   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Marien Hospital Darmstadt   (Germany)

^c Leopoldina Hospital   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g KLINIKUM FULDA   (Germany)

^h Hospital Esslingen   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

^k UNIVERSITY HOSPITAL ULM   (Germany)

^l JENA UNIVERSITY HOSPITAL   (Germany)

^m UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

Advanced biliary tract cancer; BTC; c kit; Hand foot syndrome; Hif1 ; PDGFR ; Sorafenib; VEGFR 2; VEGFR 3

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DEOXYCYTIDINE; NICOTINAMIDE; STROMAL CELL DERIVED FACTOR 1;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD SAMPLING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLANGITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GALLBLADDER NEOPLASMS; HAND-FOOT SYNDROME; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CHEMOKINE CXCL12; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALLBLADDER NEOPLASMS; HAND-FOOT SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84925224759     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.09.013     Document Type: Article

References (35)

1. D. Malka, C. Dromain, B. Landi, F. Prat, T. DeBaere, and J.R. Delpero Cancers of the biliary system Gastroenterol Clin Biol 30 Spec No 2 2006 2S62-74
2. A.D. Wagner, P. Buechner-Steudel, M. Moehler, H. Schmalenberg, R. Behrens, and J. Fahlke Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials Br J Cancer 101 11 2009 1846 1852
3. F. Eckel, and R.M. Schmid Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 6 2007 896 902
4. J. Valle, H. Wasan, D.H. Palmer, D. Cunningham, A. Anthoney, and A. Maraveyas Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 14 2010 1273 1281
5. T. Okusaka, K. Nakachi, A. Fukutomi, N. Mizuno, S. Ohkawa, and A. Funakoshi Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan Br J Cancer 103 4 2010 469 474
6. C.D. Fingas, J.C. Mertens, N. Razumilava, S.F. Bronk, A.E. Sirica, and G.J. Gores Targeting PDGFR-beta in cholangiocarcinoma Liver Int 32 3 2012 400 409
7. L.H. Jensen, J. Lindebjerg, J. Ploen, T.F. Hansen, and A. Jakobsen Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer Ann Oncol 23 9 2012 2341 2346
8. J.B. Andersen, B. Spee, B.R. Blechacz, I. Avital, M. Komuta, and A. Barbour Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Gastroenterology 142 4 2012 1021 1031
9. J.H. Yoon, H. Higuchi, N.W. Werneburg, S.H. Kaufmann, and G.J. Gores Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line Gastroenterology 122 4 2002 985 993
10. J.A. Gollob, S. Wilhelm, C. Carter, and S.L. Kelley Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 33 4 2006 392 406
11. A. Tannapfel, F. Sommerer, M. Benicke, A. Katalinic, D. Uhlmann, and H. Witzigmann Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 52 5 2003 706 712
12. C. Benckert, S. Jonas, T. Cramer, Z. von Marschall, G. Schäfer, and M. Peters Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells Cancer Res 63 5 2003 1083 1092
13. E.P. Berthiaume, and J. Wands The molecular pathogenesis of cholangiocarcinoma Semin Liver Dis 24 2 2004 127 137
14. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
15. B.R. Blechacz, R.L. Smoot, S.F. Bronk, N.W. Werneburg, A.E. Sirica, and G.J. Gores Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 Hepatology 50 6 2009 1861 1870
16. A. Huether, M. Höpfner, V. Baradari, D. Schuppan, and H. Scherbül Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma Biochem Pharmacol 73 9 2007 1308 1317
17. J.Y. Cho, Y.H. Paik, H.Y. Lim, Y.G. Kim, H.K. Lim, and Y.W. Min Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma Liver Int 33 6 2013 950 957
18. T. Otsuka, Y. Eguchi, S. Kawazoe, K. Yanagita, K. Ario, and K. Kitahara Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib Hepatol Res 42 9 2012 879 886
19. B. Vincenzi, D. Santini, A. Russo, R. Addeo, F. Giuliani, and L. Montella Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib Oncologist 15 1 2010 85 92
20. L.L. Siu, A. Awada, C.H. Takimoto, M. Piccart, B. Schwartz, and T. Giannaris Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer Clin Cancer Res 12 1 2006 144 151
21. M. Moehler, A. Mueller, J.T. Hartmann, M.P. Ebert, S.E. Al-Batran, and P. Reimer An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer Eur J Cancer 47 10 2011 1511 1520
22. M. Iavarone, G. Cabibbo, F. Piscaglia, C. Zavaglia, A. Grieco, and E. Villa Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy Hepatology 54 6 2011 2055 2063
23. A. Poprach, T. Pavlik, B. Melichar, I. Puzanov, L. Dusek, and Z. Bortlicek Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study Ann Oncol 23 12 2012 3137 3143
24. T.C. Wehler, S. Hamdi, A. Maderer, C. Graf, I. Gockel, and I. Schmidtmann Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft-no benefit of combination therapy Int J Colorectal Dis 28 3 2013 385 398
25. A.X. Zhu, M. Ancukiewicz, J.G. Supko, D.V. Sahani, L.S. Blaszkowsky, and J.A. Meyerhardt Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study Clin Cancer Res 19 6 2013 1557 1566
26. G. Collet, N. Lamerant-Fayel, M. Tertil, B. El Hafny-Rahbi, J. Stepniewski, and A. Guichard Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth Mol Cancer Ther 13 1 2014 165 178
27. H.Y. Seo, J.M. Park, K.H. Park, S.J. Kim, S.C. Oh, and B.S. Kim Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients Jpn J Clin Oncol 40 12 2010 1147 1153
28. B. Gruenberger, J. Schueller, U. Heubrandtner, F. Wrba, D. Tamandl, and K. Kaczirek Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study Lancet Oncol 11 12 2010 1142 1148
29. D. Malka, P. Cervera, S. Foulon, T. Trarbach, C. de la Fouchardiere, and E. Boucher Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial Lancet Oncol 15 8 2014 819 828
30. A.B. El-Khoueiry, C.J. Rankin, E. Ben-Josef, H.J. Lenz, P.J. Gold, and R.D. Hamilton SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma Invest New Drugs 30 4 2012 1646 1651
31. C. Bengala, F. Bertolini, N. Malavasi, C. Boni, E. Aitini, and C. Dealis Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial Br J Cancer 102 1 2009 68 72
32. S. Thongprasert, J.H. Yi, J. Lee, D.C. Doval, S.H. Park, and J.O. Park A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study Eur J Cancer 48 2 2012 196 201
33. A.X. Zhu, J.A. Meyerhardt, L.S. Blaszkowsky, A.R. Kambadakone, A. Muzikansky, and H. Zheng Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study Lancet Oncol 11 1 2009 48 54
34. J. Lee, S.H. Park, H.M. Chang, J.S. Kim, H.J. Choi, and M.A. Lee Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study Lancet Oncol 13 2 2012 181 188
35. Y. Pignochino, I. Sarotto, C. Peraldo-Neia, J.Y. Penachioni, G. Cavalloni, and G. Migliardi Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas BMC Cancer 10 2010 631